Masimo Co. (NASDAQ:MASI) Shares Sold by RTW Investments LP

RTW Investments LP lowered its position in Masimo Co. (NASDAQ:MASI - Free Report) by 53.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 683,294 shares of the medical equipment provider's stock after selling 779,106 shares during the quarter. Masimo comprises about 1.7% of RTW Investments LP's portfolio, making the stock its 24th largest position. RTW Investments LP owned 1.28% of Masimo worth $112,948,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Barclays PLC raised its position in Masimo by 152.6% in the 3rd quarter. Barclays PLC now owns 39,957 shares of the medical equipment provider's stock worth $5,329,000 after purchasing an additional 24,137 shares during the period. Fifth Third Wealth Advisors LLC bought a new position in shares of Masimo during the fourth quarter valued at approximately $241,000. Assenagon Asset Management S.A. grew its stake in shares of Masimo by 916.1% during the fourth quarter. Assenagon Asset Management S.A. now owns 216,051 shares of the medical equipment provider's stock valued at $35,713,000 after buying an additional 194,788 shares during the last quarter. Trust Co. of Vermont purchased a new stake in shares of Masimo in the fourth quarter worth approximately $33,000. Finally, HB Wealth Management LLC bought a new stake in shares of Masimo during the 4th quarter worth approximately $201,000. Hedge funds and other institutional investors own 85.96% of the company's stock.

Masimo Stock Down 3.5%

Shares of MASI stock traded down $5.48 during mid-day trading on Wednesday, hitting $150.69. The stock had a trading volume of 220,627 shares, compared to its average volume of 650,000. Masimo Co. has a 12-month low of $101.61 and a 12-month high of $194.88. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The firm's 50-day moving average is $159.81 and its two-hundred day moving average is $167.57. The firm has a market capitalization of $8.17 billion, a P/E ratio of 104.72 and a beta of 1.23.

Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.12. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm had revenue of $372.00 million during the quarter, compared to the consensus estimate of $367.79 million. During the same period in the previous year, the company posted $0.77 earnings per share. The firm's quarterly revenue was down 24.5% on a year-over-year basis. On average, analysts predict that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Insider Transactions at Masimo

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the transaction, the director now owns 16,581 shares in the company, valued at $2,754,601.53. The trade was a 11.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the transaction, the chief operating officer now owns 24,172 shares of the company's stock, valued at $4,048,568.28. This represents a 55.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,053 shares of company stock valued at $6,998,565. Company insiders own 16.90% of the company's stock.

Analyst Ratings Changes

MASI has been the subject of a number of recent analyst reports. Needham & Company LLC restated a "hold" rating on shares of Masimo in a report on Thursday, April 10th. Raymond James decreased their target price on Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Wells Fargo & Company cut their price target on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. BTIG Research set a $193.00 price objective on shares of Masimo and gave the company a "buy" rating in a report on Wednesday, May 7th. Finally, Piper Sandler reissued an "overweight" rating and issued a $200.00 price objective (down from $215.00) on shares of Masimo in a research report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $191.60.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.